Last reviewed · How we verify

Placebo of Lyrica

KunWha Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

Placebo of Lyrica is a Small molecule drug developed by KunWha Pharmaceutical Co., Ltd.. It is currently in Phase 3 development.

This is a placebo control formulation used in clinical trials to compare against the active drug Lyrica (pregabalin).

At a glance

Generic namePlacebo of Lyrica
SponsorKunWha Pharmaceutical Co., Ltd.
ModalitySmall molecule
PhasePhase 3

Mechanism of action

As a placebo, this formulation contains no active pharmaceutical ingredient and serves as a control arm in phase 3 clinical trials. It allows researchers to isolate the true therapeutic effect of pregabalin by comparing outcomes in patients receiving placebo versus the active drug. Placebos are essential for blinded, randomized controlled trials to establish efficacy and safety profiles.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo of Lyrica

What is Placebo of Lyrica?

Placebo of Lyrica is a Small molecule drug developed by KunWha Pharmaceutical Co., Ltd..

How does Placebo of Lyrica work?

This is a placebo control formulation used in clinical trials to compare against the active drug Lyrica (pregabalin).

Who makes Placebo of Lyrica?

Placebo of Lyrica is developed by KunWha Pharmaceutical Co., Ltd. (see full KunWha Pharmaceutical Co., Ltd. pipeline at /company/kunwha-pharmaceutical-co-ltd).

What development phase is Placebo of Lyrica in?

Placebo of Lyrica is in Phase 3.

Related